NEWS
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease
Soligenix (SNGX) has initiated patient enrollment for a Phase 2 clinical trial evaluating SGX945 (dusquetide) in treating Behçet's Disease.
The study received clearance from both FDA and Turkish authorities. The open-label trial will enroll approximately 25 patients with mild to moderate Behçet's Disease and active oral/genital ulcers.
Patients will receive twice-weekly IV infusions for 4 weeks, followed by 4 weeks of follow-up.
The company expects to announce results in the first half of 2025.
The disease affects up to 18,000 people in the U.S., 50,000 in Europe, 350,000 in Turkey, and about 1 million worldwide.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2606Followers
107Following
28KVisitors
Follow